Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
|
|
Fortress Biotech, Inc. (FBIO)
|
Add to portfolio |
|
|
|
| Price: |
$4.93
| | Metrics |
| OS: |
136.2
|
M
| |
|
|
| Market cap: |
$672
|
M
| |
|
|
|
Net cash:
|
$32.7
|
M
| |
$0.24
|
per share
|
|
EV:
|
$639
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($215)
|
M
| |
|
|
| EPS |
($1.01)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 75.7 | 68.8 | 45.6 | 36.6 | 26.9 | 15.5 | 16.5 | 0.9 |
| Revenue growth | 10.1% | 50.9% | 24.5% | 36.3% | 73.2% | -5.8% | 1809.6% | |
| Cost of goods sold | 35.1 | 34.6 | 16.0 | 11.7 | 6.8 | 4.2 | 0.8 | -62.8 |
| Gross profit | 40.7 | 34.2 | 29.6 | 24.9 | 20.1 | 11.3 | 15.7 | 63.7 |
| Gross margin | 53.7% | 49.8% | 64.9% | 68.0% | 74.7% | 73.0% | 95.2% | 7377.2% |
| Selling, general and administrative | 113.7 | 86.8 | 61.2 | 72.7 | 65.0 | | | |
| Sales and marketing | | | | 17.1 | 11.6 | | 5.8 | 2.9 |
| Research and development | 134.2 | 113.2 | 61.3 | 6.1 | 87.4 | 48.3 | 35.1 | 29.8 |
| General and administrative | | | | | | 50.9 | 28.2 | 18.7 |
| EBITA | -203.6 | -188.5 | -94.3 | -109.6 | -115.5 | -86.1 | -60.1 | -39.1 |
| EBITA margin | -268.8% | -274.1% | -206.7% | -299.3% | -429.7% | -554.7% | -364.7% | -4533.4% |
| Amortization of intangibles | | | | 1.2 | | | | |
| EBIT | -203.6 | -188.5 | -94.3 | -110.8 | -115.5 | -86.1 | -60.1 | -39.1 |
| EBIT margin | -268.8% | -274.1% | -206.7% | -302.5% | -429.7% | -554.7% | -364.7% | -4533.4% |
| Pre-tax income | -213.5 | -164.4 | -102.8 | -101.7 | -130.8 | -97.5 | -71.3 | -53.9 |
| Income taxes | 0.4 | 0.5 | 0.1 | 0.0 | 0.0 | 1.5 | 0.0 | 0.0 |
| Tax rate | | | | 0.0% | 0.0% | | 0.0% | 0.0% |
| Earnings from continuing ops | -86.6 | -64.7 | -46.5 | -40.0 | -59.5 | -64.6 | -55.1 | -48.4 |
| Earnings from discontinued ops | | | | | -24.6 | -2.3 | | |
| Net income | -86.6 | -64.7 | -46.5 | -40.0 | -84.1 | -66.9 | -55.1 | -48.4 |
| Net margin | -114.3% | -94.1% | -102.0% | -109.1% | -313.0% | -430.9% | -334.3% | -5611.6% |
| |
| Diluted EPS | ($0.97) | ($0.79) | ($0.65) | ($0.73) | ($1.37) | ($1.55) | ($1.38) | ($1.24) |
| Shares outstanding (diluted) | 88.9 | 81.7 | 72.0 | 54.7 | 43.5 | 41.7 | 40.0 | 39.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|